Stock SLS SELLAS LIFE SCIENCES GROUP, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials SELLAS Life Sciences Group, Inc.

Equities

SLS

US81642T2096

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 15:22:47 14/05/2024 BST 		5-day change 1st Jan Change
1.345 USD -1.82% Intraday chart for SELLAS Life Sciences Group, Inc. +1.52% +26.42%
05-01 SELLAS Life Sciences Group, Inc. Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level CI
04-29 SELLAS Life Sciences Group, Inc. Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 20.95 54.97 87.85 48.59 33.99 79.12 - -
Enterprise Value (EV) 1 20.95 54.97 87.85 48.59 33.99 79.12 79.12 79.12
P/E ratio -0.39 x -2.75 x -4.13 x -1.11 x -0.79 x -1.53 x -1.2 x -1.88 x
Yield - - - - - - - -
Capitalization / Revenue - 28.9 x 11.6 x 48.6 x - - 1.56 x 0.76 x
EV / Revenue - 28.9 x 11.6 x 48.6 x - - 1.56 x 0.76 x
EV / EBITDA - - - - - - - -
EV / FCF - - -3,376,136 x -1,404,975 x - - - -
FCF Yield - - -0% -0% - - - -
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 4,872 9,462 15,886 20,588 32,062 57,755 - -
Reference price 2 4.300 5.810 5.530 2.360 1.060 1.370 1.370 1.370
Announcement Date 13/03/20 23/03/21 31/03/22 16/03/23 28/03/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - 1.9 7.6 1 - - 50.61 104
EBITDA - - - - - - - -
EBIT 1 -17.21 -16.98 -25.29 -41.95 -37.87 -38.27 -47.05 -31.69
Operating Margin - -893.79% -332.82% -4,195% - - -92.97% -30.48%
Earnings before Tax (EBT) 1 -19.37 -16.77 -20.94 -41.3 -37.34 -40.04 -50.44 -31.55
Net income 1 -27.95 -16.84 -20.7 -41.3 -37.34 -40.04 -50.44 -31.55
Net margin - -886.05% -272.36% -4,130.1% - - -99.67% -30.35%
EPS 2 -10.92 -2.110 -1.340 -2.130 -1.340 -0.8967 -1.145 -0.7300
Free Cash Flow - - -26.02 -34.58 - - - -
FCF margin - - -342.37% -3,458.3% - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 13/03/20 23/03/21 31/03/22 16/03/23 28/03/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - - 1 - - - - - - - - - - -
EBITDA - - - - - - - - - - - - - -
EBIT 1 -6.977 -11.62 -6.735 -8.623 -7.146 -9.446 -11.28 -8.84 -9.361 -8.177 -10.03 -10.23 -10.43 -10.64
Operating Margin - - -673.5% - - - - - - - - - - -
Earnings before Tax (EBT) 1 -7.085 -6.835 -16.74 -8.414 -7.022 -9.121 -11.1 -8.84 -9.267 -8.136 -9.954 -9.963 -10.22 -10.49
Net income 1 -7.085 -6.598 -16.74 -8.414 -7.022 -9.121 -11.1 -8.84 -9.267 -8.136 -9.954 -9.963 -10.22 -10.49
Net margin - - -1,674.4% - - - - - - - - - - -
EPS 2 -0.4500 -0.4200 -1.050 -0.4100 -0.3400 -0.4300 -0.4700 -0.3100 -0.3300 -0.2500 -0.1600 -0.1600 -0.1600 -0.1300
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 12/11/21 31/03/22 12/05/22 11/08/22 14/11/22 16/03/23 11/05/23 10/08/23 09/11/23 28/03/24 - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow - - -26 -34.6 - - - -
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share - - - - - - - -
Capex - - - - - - - -
Capex / Sales - - - - - - - -
Announcement Date 13/03/20 23/03/21 31/03/22 16/03/23 28/03/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.37 USD
Average target price
6.833 USD
Spread / Average Target
+398.78%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
SELLAS LIFE SCIENCES GROUP, INC. Stock SELLAS Life Sciences Group, Inc.
+26.42% 79.12M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+4.42% 111B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+10.95% 105B
BIONTECH SE Stock BioNTech SE
-12.01% 22.34B
ARGENX SE Stock argenx SE
-3.81% 21.93B
GENMAB A/S Stock Genmab A/S
-5.94% 18.59B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-36.52% 18.12B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.04% 16.96B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.07% 13.7B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+37.10% 12.45B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. SLS Stock
  4. Financials SELLAS Life Sciences Group, Inc.